New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 17, 2013
12:46 EDTGILDGilead Issues a voluntary recall of one lot of Vistide
Gilead Sciences announced it is voluntarily recalling lot B120217A of Vistide (cidofovir injection) to the user level due to the presence of particulate matter found in some vials of this lot. Effects from intravenous injection of product with particulate matter can vary depending on the amount of particulate matter injected into the patient, the size of the particles and the patientís underlying medical condition, and can be severe. Gilead is not currently aware of any complaint attributable to the particles.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:20 EDTGILDAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
April 13, 2015
16:01 EDTGILDOptions Update; April 13, 2015
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
April 10, 2015
16:05 EDTGILDOptions Update; April 10, 2015
Subscribe for More Information
April 9, 2015
06:12 EDTGILDSovaldi prices causes Medicaid spending for hepatitis C drugs to soar, WSJ says
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
April 6, 2015
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use